Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective increased by research analysts at Wells Fargo & Company from $45.00 to $46.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 76.04% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Guggenheim reduced their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Royal Bank Of Canada raised their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Cantor Fitzgerald upped their price target on shares of Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $58.29.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $0.11 during trading hours on Thursday, hitting $26.13. The company had a trading volume of 1,585,355 shares, compared to its average volume of 2,211,932. Ultragenyx Pharmaceutical has a 1-year low of $18.29 and a 1-year high of $39.89. The company has a market cap of $2.58 billion, a PE ratio of -4.47 and a beta of 0.35. The business has a 50 day moving average of $28.52 and a 200-day moving average of $24.96.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million for the quarter, compared to analysts’ expectations of $183.08 million. During the same quarter in the previous year, the firm earned ($1.17) earnings per share. The business’s revenue was up 28.5% compared to the same quarter last year. Sell-side analysts expect that Ultragenyx Pharmaceutical will post -4.12 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the completion of the sale, the director owned 21,095 shares in the company, valued at $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president directly owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 8,552 shares of company stock valued at $207,455. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Ultragenyx Pharmaceutical by 14.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after purchasing an additional 29,984 shares during the period. Creative Planning acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $454,000. American Century Companies Inc. acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $366,000. M&T Bank Corp raised its stake in shares of Ultragenyx Pharmaceutical by 19.7% during the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 1,192 shares in the last quarter. Finally, Amundi raised its stake in shares of Ultragenyx Pharmaceutical by 1,560.4% during the 2nd quarter. Amundi now owns 99,161 shares of the biopharmaceutical company’s stock worth $3,913,000 after buying an additional 93,189 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: GENGLYCOS is the first FDA-approved treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa), a rare metabolic disorder. The therapy could reduce the daily care burden for patients and give Ultragenyx a new commercial growth driver. Reuters article
• Positive Sentiment: The approval is Ultragenyx’s first gene-therapy approval and its fifth FDA approval overall, expanding the company’s marketed product portfolio. Ultragenyx also received a Priority Review Voucher, which could potentially be used or sold for additional value. Ultragenyx announcement
• Positive Sentiment: Wells Fargo described the gene-therapy launch as capable of creating a “long revenue tailwind,” while Cantor Fitzgerald raised its price target to $103 from $96 and maintained an Overweight rating. These targets imply substantial upside, although they are analyst estimates rather than guarantees. Yahoo Finance analyst coverage
• Neutral Sentiment: The accelerated approval supports earlier commercialization, but continued approval generally depends on confirmatory evidence. Investors will focus on launch timing, treatment uptake, pricing, reimbursement and the company’s ability to generate durable revenue.
• Negative Sentiment: RARE had recently weakened ahead of the FDA decision, underscoring that expectations and execution risk remain high. Ultragenyx is still loss-making, so the near-term stock reaction may depend on whether GENGLYCOS sales can materially improve the company’s financial outlook.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.